Avantor, Inc. Provides Earnings Guidance for Full Year 2023
October 27, 2023 at 08:00 am EDT
Share
Avantor, Inc. provided earnings guidance for full year 2023 . For the year, company expected full year core organic revenue growth of negative 6% to negative 5% and organic revenue growth of negative 8.5% to negative 7.5%. In each case, this tightens their range but retains the same midpoint.
After accounting for a 50 bass-point tailwind from FX, they anticipate full year 2023 reported growth of negative 8% to negative 7%.
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
AVANTOR, INC. 
